None listed
Conditions
Brief summary
The aims of this study are to: 1) establish the extent to which extracts with glucoregulatory properties can improve mood and cognitive performance, 2) establish the optimum cognition-enhancing dose for each extract 3) determine which cognitive domains are most affected by each extract 4) examine the effects of each extract on glucose levels and cognitive function 5) examine the effect of each extract on glucose control in relation to cognitive function 6) directly compare the neurocognitive effects of optimum doses of the extracts examined in the trial
Interventions
Study 1: The study will involve an oral administration of 3 Panax aquinquefolius doses (100mg, 200mg and 400mg)
On each testing day, participants will be randomly allocated to take a treatment once immediately after baseline assessment. Following a one week washout period each volunteer will return to the testing labs an undergo the same procedure under a different dose of Panax aquinquefolius until all treatments are complete.
Study 2: The methodology will be identical to that described in stu
Study 1: The study will involve an oral administration of 3 Panax aquinquefolius doses (100mg, 200mg and 400mg) On each testing day, participants will be randomly allocated to take a treatment once immediately after baseline assessment. Following a one week washout period each volunteer will return to the testing labs an undergo the same procedure under a different dose of Panax aquinquefolius until all treatments are complete. Study 2: The methodology will be identical to that described in study 1, except three doses of Fraxinus excelsior (200mg, 400mg and 600mg) will be used. Study 3: The methodology will be identical to that described in study 1, except three doses of Rosmarinus officinalis (250mg, 500mg and 750mg) will be used. Study 4: The methodology will be identical to that described in study 1, except three doses of Spergularea purpurea (200mg, 400mg and 600mg) will be used. Study 5: The methodology will be similar to the previous studies except that it will compare the optimal doses for cognitive enhancement identified in the preceding studies.
Sponsors
Swinburne University of Technology
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Prevention
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
non-smoker, no history of anxiety, depression or psychiatric disorders not taking medication (prescription or over the counter), herbal extracts, vitamin supplements or illicit drugs no kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, celiac disease, peptic ulcers) no health conditions affecting blood glucose levels - Diabetes (Type 1 & 2), hypoglycaemia, hyperglycaemia no health conditions affecting the adrenal glands - Cushing's disease, Addison's disease not pregnant or breast feeding.
Exclusion criteria
smoker history of anxiety, depression or psychiatric disorders taking any medication (prescription or over the counter), herbal extracts, vitamin supplements or illicit drugs food allergies, kidney disease, liver disease and/or gastrointestinal diseases (e.g. Irritable bowel syndrome, celiac disease, peptic ulcers) health conditions affecting blood glucose levels - Diabetes (Type 1 & 2), hypoglycaemia, hyperglycaemia health conditions affecting the adrenal glands - Cushing's disease, Addison's disease pregnant or breast feeding.
Outcome results
None listed